Melanoma is a shape-shifting disease that outsmarts even the most advanced treatments — resistance to immunotherapy and targeted therapies remains a stubborn, unsolved problem. A promising compound from a sea squirt is still years away from clinical use, and the pipeline for patients whose cancer stops responding to existing drugs is already dangerously thin. Getting excited about early-stage marine biology while refractory patients run out of options is a luxury the field cannot afford.